Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a decrease in first-quarter 2023 adjusted earnings and revenues. The company also provided guidance for
ABBV Infographic: AbbVie’s Q1 2023 earnings and revenue decline
Categories
Biotechnology
Eli Lilly and Company (LLY) Q1 2023 Earnings Call Transcript
Eli Lilly and Company (NYSE: LLY) Q1 2023 Earnings Call dated Apr. 27, 2023 Corporate Participants: Joe Fletcher -- Senior Vice President
BSX Earnings: Highlights of Boston Scientific’s Q1 2023 results
Medical device maker Boston Scientific Corporation (NYSE: BSX) reported financial results for the first quarter of 2023. The company also provided guidance for
Illumina Inc (ILMN) Q1 2023 Earnings Call Transcript
Illumina Inc (NASDAQ: ILMN) Q1 2023 earnings call dated Apr. 25, 2023 Corporate Participants: Salli Schwartz -- Vice President of Investor Relations Francis deSouza -- Chief
Ocean Biomedical co-founder Jonathan Kurtis presents detailed data on malaria vaccine at conference
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharma company that works with research universities and medical centers for developing and commercializing their
Ocean Biomedical co-founder Jack Elias to receive US patent for pulmonary fibrosis treatments
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharma company that works with research universities and medical centers for developing and commercializing their
Ocean Biomedical (OCEA) announces $134 million financial backing for innovative research and IND filings
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company that works with research universities and medical centers for developing and commercializing their discoveries,
Ocean Biomedical gets Notice of Allowance for US patent application for developing new malaria therapeutics
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company that works with research universities and medical centers for developing and commercializing their discoveries,
Bio Path Holdings Inc (BPTH) Q4 2022 Earnings Call Transcript
Bio Path Holdings Inc (NASDAQ: BPTH) Q4 2022 earnings call dated Mar. 31, 2023 Corporate Participants: Will O'Connor -- Investor Relations Peter Nielsen -- Chief Executive
TC BioPharm develops safer, less expensive products to target more cancers: CEO Bryan Kobel
TC BioPharm (NASDAQ: TCBP) is a clinical-stage cell therapy company focused on the development of treatments for infectious diseases, including advanced allogeneic
Walgreens Boots Alliance (WBA) shifts to expansion mode. Will it pay off?
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), a market leader in retail pharmacy, has regularly revised its business model to better align with
Ocean Biomedical presents novel malaria therapeutic discoveries at NIH Laboratory of Malaria Vaccinology and Immunology
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharma company that works with research universities and medical centers for developing and commercializing their
Fundamental Research Corp. initiates coverage of Ocean Biomedical (OCEA) with “Buy” recommendation
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday said that Fundamental Research Corp. initiated equity analyst coverage of its stock with a “Buy”
Ocean Biomedical provides positive research data on anti-tumor pathway; stock climbs
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) released details of discoveries that have potential applications for tumor suppression across multiple cancer pathways.
Novavax Inc (NVAX) Q4 2022 Earnings Call Transcript
Novavax Inc (NASDAQ:NVAX) Q4 2022 Earnings Call dated Feb. 28, 2023. Corporate Participants: Erika Schultz -- Senior Director of Investor Relations John Jacobs -- President and
Ocean Biomedical co-founder Jake Kurtis gets new patent for novel malaria vaccine target
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said its scientific co-founder Dr. Jonathan Kurtis received a new patent for his discovery related
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
The global pharmaceutical market is expected to cross $1.5 trillion this year, which represents a 4-5% annual growth over the past five
Moderna (MRNA) Earnings: 4Q22 Key Numbers
Moderna Inc. (NASDAQ: MRNA) reported total revenue of $5.1 billion for the fourth quarter of 2022, down 29% year-over-year due to a
Key highlights from Biogen’s (BIIB) Q4 2022 earnings results
Biogen Inc. (NASDAQ: BIIB) reported fourth quarter 2022 earnings results today. Total revenue fell 7% year-over-year to $2.54 billion. Net income attributable
AbbVie sees near-term slowdown; looks prepared to tackle patent expiration
AbbVie, Inc. (NYSE: ABBV) has delivered yet another quarter of strong top-line and earnings performance but issued cautious guidance for fiscal 2023
Veru Inc (VERU) Q1 2023 Earnings Call Transcript
Veru Inc (NASDAQ: VERU) Q1 2023 earnings call dated Feb. 09, 2023 Corporate Participants: Sam Fisch -- Executive Director, Investor Relations, and Corporate Communications Mitchell